US 12,258,614 B2
Hybridization chain reaction-based method for amplifying immunosignals
Rui Lin, Beijing (CN); and Minmin Luo, Beijing (CN)
Assigned to GenAns Biotechnology Co., Ltd., Beijing (CN)
Appl. No. 16/964,386
Filed by GenAns Biotechnology Co., Ltd., Beijing (CN)
PCT Filed Jan. 26, 2018, PCT No. PCT/CN2018/074362
§ 371(c)(1), (2) Date Jul. 23, 2020,
PCT Pub. No. WO2019/144389, PCT Pub. Date Aug. 1, 2019.
Prior Publication US 2020/0377926 A1, Dec. 3, 2020
This patent is subject to a terminal disclaimer.
Int. Cl. C12Q 1/6804 (2018.01); C12Q 1/6818 (2018.01); G01N 33/68 (2006.01)
CPC C12Q 1/6804 (2013.01) [C12Q 1/6818 (2013.01); G01N 33/6854 (2013.01); C12Q 2563/107 (2013.01); G01N 2458/10 (2013.01)] 21 Claims
OG exemplary drawing
 
1. An immunosignal Hybridization Chain Reaction (isHCR), which comprises conjugating a hybridization chain reaction (HCR) initiator to an antibody specific to an analyte, and adding a pair of HCR amplifiers to conduct a hybridization chain reaction, wherein an amplifier or a pair of amplifiers are modified to perform branched multiple-round amplification in order to branch and grow HCR polymers, and the amplifier or the pair of amplifiers are internally modified with a chemical group and/or a fluorescent dye which initiates further rounds of amplification.